MacroGenics
MacroGenics is a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics — including bispecific DART molecules, ADCs, and T-cell engagers — for oncology, hematology, and autoimmune diseases, commercializing through licensing partnerships with Sanofi, Incyte, and Gilead.
- Company typePublic
- Founded2000
- HeadquartersRockville, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What MacroGenics does
MacroGenics is a clinical-stage biopharmaceutical company founded in 2000 and headquartered in Rockville, Maryland, that develops antibody-based therapeutics for cancer, autoimmune disease, and infectious disease. Its pipeline is built on four proprietary protein-engineering platforms: DART® (bispecific antibodies), TRIDENT® (trivalent bispecifics with CD137 costimulation), an antibody-drug conjugate (ADC) platform, and an Fc optimization platform. Lead wholly-owned clinical assets include lorigerlimab (PD-1 × CTLA-4 bispecific, Phase 2 LINNET), MGC026 (B7-H3 ADC, Phase 1), MGC028 (ADAM9 ADC, Phase 1), MGD024 (CD123 × CD3, Phase 1), and MGC030 (IND-enabling, Q3 2026 submission planned).
The company generates revenue primarily through licensing and milestone payments on partnered assets rather than direct product sales. Three FDA-approved products have originated from its pipeline: TZIELD (teplizumab, licensed to Sanofi for type 1 diabetes), ZYNYZ (retifanlimab, licensed to Incyte for PD-1 inhibitor indications), and margetuximab (anti-HER2). MacroGenics retains development control and earns milestones, royalties, and opt-in fees; it has also monetized royalty streams via a $60M capped royalty purchase with Sagard Healthcare Partners on ZYNYZ. In May 2026 MacroGenics agreed to sell its in-house GMP drug substance manufacturing operations to Bora Pharmaceuticals for $122.5M upfront, transferring approximately 140 employees and pivoting to a pipeline-focused model with contract-manufacturing supply. Customers are global pharmaceutical partners (Sanofi, Incyte, Gilead), not end patients or providers, and revenue is recognized when milestones or royalties are earned under these collaboration agreements.
MacroGenics firmographics
Firmographics- Name
- MacroGenics
- Legal name
- MacroGenics, Inc.
- Website
- https://macrogenics.com
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- MacroGenics is a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics — including bispecific DART molecules, ADCs, and T-cell engagers — for oncology, hematology, and autoimmune diseases, commercializing through licensing partnerships with Sanofi, Incyte, and Gilead.
- Ownership category
- akta.pro rank
MacroGenics industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)
Keywords
Where MacroGenics is headquartered
LocationHeadquarters
- HQ city
- Rockville
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
MacroGenics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Licensing and Royalty Revenue: MacroGenics generates revenue through licensing agreements with pharmaceutical partners. The company licenses its developed products to partners like Incyte (ZYNYZ/retifanlimab) and receives milestone payments, royalty payments on net sales, and potential opt-in fees.
- Milestone Payments: The company receives regulatory and commercial milestone payments from partners upon achievement of predetermined development and approval milestones. Recent example: $24.5M from Sanofi for TZIELD FDA accelerated approval.
- Royalty Monetization: MacroGenics sells capped royalty interests to financial partners (e.g., Sagard Healthcare Partners) for upfront non-dilutive capital. The company received $60M upfront from Sagard for ZYNYZ royalties, with rights reverting after specified return thresholds.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
MacroGenics product offering
Product offeringCore offering
MacroGenics is a clinical-stage biopharmaceutical company that discovers and develops next-generation antibody-based therapeutics for cancer, hematologic malignancies, and autoimmune diseases. Its pipeline encompasses bispecific checkpoint antibodies, antibody-drug conjugates (ADCs), and T-cell engagers built on proprietary DART®, TRIDENT®, ADC, and Fc Optimization platforms, with three FDA-approved therapies (TZIELD, ZYNYZ, margetuximab) licensed to large pharma partners for global commercialization.
Product overview
MacroGenics is a clinical-stage biopharmaceutical company developing next-generation antibody-based therapies for cancer treatment. The company's proprietary technology platforms include DART® (bispecific antibodies), TRIDENT® (trivalent bispecifics), and Fc Optimization. The core pipeline consists of proprietary candidates including Lorigerlimab (PD-1×CTLA-4 bispecific), MGC026 (B7-H3 ADC), MGC028 (ADAM9 ADC), MGD024 (CD123×CD3), and MGC030. MacroGenics also advances partnered programs including TZIELD (Type 1 Diabetes, licensed to Sanofi), ZYNYZ/retifanlimab (PD-1 inhibitor, licensed to Incyte), Flotetuzumab, Tebotelimab, Margetuximab, and IMGC936. The company operates manufacturing capabilities in Maryland and has strategic collaborations with Incyte, Gilead, and Sanofi.
Differentiator
Problem solved
Functional benefit
Brands
- TZIELD: Disease-modifying therapy for type 1 diabetes (teplizumab-mzwv) - FDA approved for delaying decline in endogenous insulin production in children aged 8-17 with stage 3 type 1 diabetes
- ZYNYZ
Products and services
- Lorigerlimab (MGD019) Bispecific DART molecule simultaneously targeting PD-1 and CTLA-4 checkpoint receptors to deliver enhanced anti-tumor activity in solid tumors, with the Phase 2 LINNET study evaluating the candidate in gynecologic cancers.
- MGC026 (B7-H3 ADC) Glycan-linked, exatecan-based antibody-drug conjugate targeting B7-H3 for the treatment of solid tumors, currently in a Phase 1 clinical study.
- MGC028 (ADAM9 ADC) ADAM9-targeted, glycan-linked, exatecan-based antibody-drug conjugate for the treatment of solid tumors, currently in a Phase 1 clinical study.
- MGD024 (CD123 × CD3) Bispecific DART molecule targeting CD123 and CD3 for treatment of hematological malignancies, particularly acute myeloid leukemia (AML), currently in a Phase 1 clinical trial.
- MGC030
Quantifiable outcome
- FDA accelerated approval of TZIELD (teplizumab) as first disease-modifying therapy for type 1 diabetes
- +2 more outcomes
Companies that use MacroGenics
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
MacroGenics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
MacroGenics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- SanoficoreMacroGenics partnered with Sanofi for TZIELD (teplizumab), a drug for delaying the decline of endogenous insulin production in children aged 8-17 with stage 3 type 1 diabetes. Sanofi holds commercialization rights while MacroGenics receives milestone payments and royalties. MacroGenics received a $24.5M regulatory milestone following FDA accelerated approval and is eligible for up to $305M in additional milestones plus single-digit royalties on global net sales.
- Bora PharmaceuticalscoreBora Pharmaceuticals acquired MacroGenics' GMP drug substance manufacturing operations including the Rockville, Maryland facility and Frederick warehouse for $122.5M upfront plus up to $5M milestones. Approximately 140 employees transferred to Bora. The transaction shifts MacroGenics to a pipeline-focused model while maintaining access to manufacturing through a long-term supply arrangement. Expected to close Q3 2026.
- Incyte CorporationcoreGlobal collaboration for ZYNYZ (retifanlimab), a PD-1 inhibitor originally developed by MacroGenics and licensed to Incyte. Incyte markets ZYNYZ in the US for Merkel cell carcinoma and anal cancer, with European Commission approval secured for anal cancer. MacroGenics eligible for up to $540M in milestones.
- Gilead SciencescoreStrategic collaboration for multiple programs with MacroGenics eligible for up to $1.6 billion in potential milestones across all programs.
Scale indicators11 records
Recent moves7 records
Expansion highlights5 records
MacroGenics competitors and assessment
Company assessmentDirect peers
- Genmab: Genmab is a leading bispecific antibody platform company (Duobody® platform) and developer of approved therapeutics including epcoritamab. Highly comparable to MacroGenics given shared focus on bispecific antibody engineering and oncology/hematology indications.
- Zymeworks: Zymeworks develops bispecific and multifunctional antibody therapeutics using its Azymetric™ and EFECT™ platforms. Directly comparable as a clinical-stage antibody engineering company pursuing similar oncology targets and partnership-driven commercialization strategies.
- Mersana Therapeutics: Mersana develops antibody-drug conjugates using its Dolasynthen and Immunosynthen platforms, focused on oncology indications. Closely comparable to MacroGenics' ADC franchise (MGC026, MGC028) given shared modality focus and clinical-stage profile.
- Harpoon Therapeutics: Harpoon develops T-cell engagers using its TriTAC and ProTriTAC platforms, including HP568 and other clinical-stage oncology assets. Directly comparable to MacroGenics' TRIDENT® T-cell engager platform and bispecific checkpoint approach.
- Bolt Biotherapeutics: Bolt is a clinical-stage ADC developer using its Boltbody™ ISAC platform combining tumor-targeting antibodies with immune stimulants. Comparable to MacroGenics' ADC pipeline given shared focus on next-generation antibody-drug conjugate modalities in oncology.
Emerging players
- CytomX Therapeutics: CytomX develops probody therapeutics — masked antibodies activated in the tumor microenvironment — with multiple partnered programs. Comparable to MacroGenics given shared focus on engineering antibody-based cancer therapeutics with proprietary platforms and major pharma collaborations.
- Compass Therapeutics: Compass Therapeutics is a clinical-stage bispecific antibody developer (CTX-009, CTX-112) with platforms in oncology. Comparable as a smaller-scale bispecific antibody developer with similar clinical-stage profile and partnership-oriented business model.
Broad incumbents
- Exelixis: Exelixis is a commercial-stage oncology biotech (cabozantinib/CABOMETYX) with a marketed product franchise and pipeline. Comparable to MacroGenics as an oncology-focused biotech, though Exelixis is significantly larger and operates a direct commercial model versus MacroGenics' partner-driven approach.
- Blueprint Medicines: Blueprint Medicines is a commercial-stage precision oncology company (AYVAKIT, GAVRETO). Comparable as a similarly sized clinical/commercial biotech with partnered and proprietary oncology assets, though Blueprint has broader kinase inhibitor focus versus MacroGenics' antibody focus.
- Iovance Biotherapeutics: Iovance is a clinical/commercial-stage cell therapy company (AMTAGVI for melanoma) at a comparable scale to MacroGenics. Comparable as a similarly-sized public biotech with FDA-approved therapy, ongoing clinical pipeline, and capital needs typical of late-stage biotech.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
MacroGenics social profiles
Digital presenceMacroGenics financial estimates
Financial estimateRevenue estimate
Valuation estimate
MacroGenics leadership team
Management profileNumber of profiles
Profiles11 records
MacroGenics funding detail
Funding detailFunding overview
Funding rounds10 records
Investors25 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MacroGenics M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MacroGenics
What does MacroGenics do?
MacroGenics is a clinical-stage biopharmaceutical company that discovers and develops next-generation antibody-based therapeutics for cancer, hematologic malignancies, and autoimmune diseases. Its pipeline encompasses bispecific checkpoint antibodies, antibody-drug conjugates (ADCs), and T-cell engagers built on proprietary DART®, TRIDENT®, ADC, and Fc Optimization platforms, with three FDA-approved therapies (TZIELD, ZYNYZ, margetuximab) licensed to large pharma partners for global commercialization.
Is MacroGenics a public or private company?
MacroGenics is a public company. It is classified as public and is currently operating.
When was MacroGenics founded?
MacroGenics was founded in 2000. It employs 251 to 500 people.
Where is MacroGenics based?
MacroGenics is headquartered in Rockville, United States, in the North America region.
How does MacroGenics make money?
Three revenue lines are on record. Licensing and Royalty Revenue is the primary driver. The others are milestone Payments and royalty Monetization.
Who are MacroGenics's main competitors?
Direct peers on record are Genmab, Zymeworks, Mersana Therapeutics, Harpoon Therapeutics and Bolt Biotherapeutics. Emerging players are CytomX Therapeutics and Compass Therapeutics. Broad incumbents are Exelixis, Blueprint Medicines and Iovance Biotherapeutics.
Does MacroGenics have an API?
No public API is recorded for MacroGenics.
What industry is MacroGenics in?
MacroGenics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.